OncoMatch/Clinical Trials/NCT06666270
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Is NCT06666270 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies SYN818 for advanced solid cancer.
Treatment: SYN818 — This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Ovarian Cancer
Breast Carcinoma
Prostate Cancer
Biomarker criteria
Required: BRCA1 mutation
Required: BRCA2 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care
disease progression, and available SOC therapies had been exhausted
Cannot have received: POLQ inhibitor
Previous or current use of POLQ inhibitors
Lab requirements
Blood counts
No serious hematological diseases other than the primary disease; adequate bone marrow function
Kidney function
No serious kidney diseases other than the primary disease; adequate organ function
Liver function
No serious liver diseases other than the primary disease; adequate organ function
Cardiac function
No serious cardiopulmonary diseases other than the primary disease
No serious hematological, cardiopulmonary, or liver or kidney diseases other than the primary disease; Adequate organ function and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06666270 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior POLQ inhibitor disqualifies patients from enrollment.
Does this trial require BRCA1?
Yes, BRCA1 mutation is a required biomarker for enrollment.
Does this trial require BRCA2?
Yes, BRCA2 mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify